�������ýҕ�l

A new study suggests the messenger RNA vaccines produced by Moderna and the Pfizer-BioNTech partnership appeared to be 90% effective in preventing Covid-19 infection in a real-world setting. ... The study followed nearly 4,000 health care workers, first responders, and other essential workers in eight U.S. locations as the first Covid vaccines were rolled out starting in December. Participants were tested weekly to look for all cases of Covid infection, even asymptomatic ones. (Branswell, 3/29)

COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced risk of infection by 80% two weeks or more after the first of two shots, according to data from a real-world U.S. study released on Monday. ... The results validate earlier studies that had indicated the vaccines begin to work soon after a first dose, and confirm that they also prevent asymptomatic infections. Some countries dealing with limited vaccine supplies have pushed back schedules for second doses with the hope of getting some protection to more people. U.S. public health officials, however, continue to recommend two doses be given on the schedule authorized by regulators based on clinical trials. (Banerjee and Chander, 3/29)

The new CDC findings are likely to bolster arguments from some health experts and public health officials that the U.S. should prioritize giving Americans just one dose of the vaccines before moving on to second doses, accelerating the pace of vaccinations across the nation. (Lovelace Jr., 3/29)

In addition, the data indicated the vaccines can reduce the risk of coronavirus infections whether or not they cause symptoms, the CDC said. “This study shows that our national vaccination efforts are working,” CDC Director Dr. Rochelle Walensky said. “The authorized vaccines are the key tool that will help bring an end to this devastating pandemic.” (Hopkins, 3/29)